CureVac and EC advanced discussions to supply up to 405 million doses of potential mRNA-based COVID-19 vaccine
On Aug. 20, 2020, CureVac and the European Commission (EC) concluded exploratory talks outlining an Advanced Purchase Agreement…
Sorrento announced agreement to acquire SmartPharm and develop gene-encoded therapeutic antibodies for COVID-19 and cancer therapeutics
On Aug. 20, 2020, Sorrento Therapeutics and SmartPharm Therapeutics announced the signing of a merger agreement under which…
Pfizer and BioNTech shared positive early data on lead mRNA vaccine candidate BNT162b2 against COVID-19
On Aug. 20, 2020, Pfizer and BioNTech shared additional Phase 1 safety and immunogenicity data from their U.S….
Bio-Techne and Leica Biosystems are acceleratied disease research with RNAscopeﾙ COVID-19 probes and the BOND RX
On Aug. 19, 2020, Bio-Techne in partnership with Leica Biosystems, announced the automation of RNAscopeﾙ COVID-19 probes on…
Pfizer and BioNTech announced publication of peer-reviewed data from phase 1/2 study of mRNA-based vaccine candidate
On Aug. 12, 2020, Pfizer and BioNTech announced that preliminary, peer-reviewed data from their BNT162 mRNA-based vaccine development…
Moderna announced supply agreement with U.S. Government for initial 100 million doses of mRNA vaccine against COVID-19
On Aug. 11, 2020, Moderna announced that the U.S. government had secured 100 million doses of mRNA-1273. The…
NIH-Moderna investigational COVID-19 vaccine showed promise in mouse studies
On Aug. 5, 2020, the National Institute of Allergy and Infectious Diseases (NIAID) announced that the investigational vaccine…
Pfizer and BioNTech to supply Canada with their BNT162 mRNA- based vaccine candidate
On Aug. 5, 2020, Pfizer Canada and BioNTech announced an agreement with the Government of Canada to supply…
Pfizer and BioNTech announced an agreement with the MHLW in Japan to supply 120 million doses of BNT162 mRNA-based vaccine candidate
On Jul. 31, 2020, Pfizer and BioNTech announced an agreement with the Ministry of Health, Labour and Welfare…
Veracyte and MAVIDx announcd agreement for MAVIDx to develop ultra-high volume COVID-19 testing on the nCounter System
On Jul. 29, 2020, Veracyte and MAVIDx announced an agreement for MAVIDx to develop ultra-high throughput genomic testing…
FDA authorized Quest Diagnostics lab method designed to increase COVID-19 molecular diagnostics capacity
On Jul. 29, 2020, Quest Diagnostics announced that the FDA had granted emergency use authorization for a new…
Moderna announced publication in the NEJM of non-human primate preclinical viral challenge study of its mRNA vaccine against COVID-19
On Jul. 28, 2020, Moderna announced a preclinical study evaluating mRNA-1273, its vaccine candidate against COVID-19, was published…
Phase 3 clinical trial of investigational vaccine for COVID-19 began
On Jul. 27, 2020, the National Institutes of Health (NIH) announced that a phase 3 clinical trial designed…
Amyris and the Infectious Disease Research Institute partnered to advance novel RNA vaccine platform beginning with COVID-19 application
On Jul. 27, 2020, Amyris and the Infectious Disease Research Institute (IDRI) announced the signing of a binding…
Moderna announced phase 3 COVE study of mRNA vaccine against COVID-19 (mRNA-1273) began
On Jul. 27, 2020, Moderna announced that the Phase 3 study of its mRNA vaccine candidate (mRNA-1273) against…
Moderna announced expansion of BARDA agreement to support larger phase 3 program for vaccine (mRNA-1273) against COVID-19
On Jul. 26, 2020, Moderna announced a modification to its contract with the Biomedical Advanced Research and Development…
Experimental Coronavirus vaccine is safe and produced immune response
On Jul. 21, 2020, National Institutes of Health (NIH) researchers reported early results from the first COVID-19 vaccine…
GSK and CureVac announced strategic mRNA technology collaboration
On Jul. 21, 2020, GlaxoSmithKline and CureVac announced a strategic collaboration agreement for the research, development, manufacturing and…
Experimental coronavirus vaccine reported safe and produces immune response
On Jul. 21, 2020, researchers from the National Institutes of Health (NIH) announced that early results from the…
Pfizer and BioNTech announced sgreement with the UK for 30 million doses of mRNA-based vaccine candidate against SARS-CoV-2
On Jul. 20, 2020, Pfizer and BioNTech announced an agreement with the United Kingdom to supply 30 million…
Pfizer and BioNTech announced early positive update from German phase 1/2 COVID-19 vaccine study
On Jul. 20, 2020, BioNTech and Pfizer announced initial data from their ongoing German Phase 1/2, open-label, non-randomized,…
HDT BIOﾒs COVID-19 vaccine candidate HDT-301 induced neutralizing antibody responses after single injection
On Jul. 20, 2020, scientists at HDT Bio, PAI Life Sciences, and the University of Washington announced they…
Placenta lacks major molecules used by SARS-CoV-2 virus to cause infection
On Jul. 14, 2020, a study by NIH researchers reported the placental membranes that contain the fetus and…
Experimental COVID-19 vaccine safe, generated immune response
On Jul. 14, 2020, an investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus…
Moderna announced publication in The New England Journal of Medicine of interim results from phase 1 study of its mRNA vaccine against COVID-19
On Jul. 14, 2020, Moderna announced the publication of an interim analysis of the open-label Phase 1 study…
Pfizer and BioNTech granted FDA Fast Track Designation for two investigational mRNA-based vaccine candidates against SARS-CoV-2
On Jul. 13, 2020, Pfizer and BioNTech announced that two of the companiesﾒ four investigational vaccine candidates from…
Moderna and ROVI announced collaboration for OUS fill-finish manufacturing of Moderna’s COVID-19 vaccine candidate
On Jul. 9, 2020 Moderna and Laboratorios Farmaceuticos Rovi announced a collaboration for large-scale, commercial fill-finish manufacturing of…
Moderna completed enrollment of phase 2 study of its mRNA vaccine against COVID-19 (mRNA-1273)
On Jul. 8, 2020, Moderna announced that it had completed enrollment for both cohorts of the Phase 2…
Pfizer and BioNTech announced early positive data from ongoing phase 1/2 study of mRNA-based vaccine candidate against SARS-CoV-2
On Jul. 1, 2020, Pfizer and BioNTech announced preliminary data from the most advanced of four investigational vaccine…
Moderna and Catalent announced collaboration for fill-finish manufacturing of Moderna’s COVID-19 vaccine candidate
On Jun. 25, 2020 Moderna announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine…